ArticleDiscover oncology2025
Potential of circulating miR-6875 and miR-1307 as non-invasive diagnostic biomarkers for pancreatic cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimPancreatic cancer (PC) is marked by high mortality and resistance to conventional therapies, largely due to a dense desmoplastic stroma that promotes drug resistance and metastasis. This highlights the need for specific non-invasive diagnostic markers. MicroRNAs (miRNAs), known for regulating gene expression and influencing tumor behavior, have emerged as promising biomarkers. This study aimed to evaluate the expression of circulating miR-6875 and miR-1307 in PC patients to explore their diagnostic potential.
methodsBlood, urine, and saliva samples were collected from 20 PC patients and 12 healthy controls. RNA extraction and cDNA synthesis were performed following standard protocols, and quantitative real-time PCR assays were used to quantify miR-6875 and miR-1307 expression levels. Statistical analysis was performed to predict their diagnostic potential and association with clinical and biochemical parameters of PC patients.
resultsOur results revealed significantly elevated levels of miR-6875 and miR-1307 in plasma, urine samples, and saliva samples from PC patients compared to controls. Receiver operating characteristic (ROC) curve analysis demonstrated the potential of miR-6875 and miR-1307 in plasma as diagnostic biomarkers for PC, with AUC values of 0.79 and 0.83, respectively.
conclusionPlasma levels of miR-6875 and miR-1307 show potential as non-invasive diagnostic biomarkers for pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.